• There are no suggestions because the search field is empty.

Handling Medical Information Requests and Enquiries: A Scientific Services Guide

person-image
Ana María González Fuente, Senior Consultant Medical Information at QbD Group

Learn how to handle medical information requests and enquiries in line with EU and local pharma regulations. Best practices for scientific services teams.

Guide to Medical Information Requests and Enquiries | QbD Group
10:41

What do you do when a healthcare professional emails your company about off-label use

  • Or when a patient wants clarity on a side effect they’ve experienced?
  • Or when a patient isn’t sure how to operate their medical device?
  • Or when a patient forgets a dose and needs guidance?
  • Or when a pharmacist runs into problems with the storage and stability of your product?

These aren’t just routine inquiries — they’re Medical Information Requests (or Medical Enquiries), and the way you handle them can shape everything from your compliance status to brand trust.

In today’s highly regulated pharmaceutical environment, every request is a moment of truth. They test not only your scientific credibility, but also your ability to respond clearly, compassionately, and in full compliance with national and European regulations.

In this post, we’ll walk you through the lifecycle of a medical enquiry, highlight the skills and systems you need to manage them effectively, and show how a simple question can evolve into a critical regulatory touchpoint.

What are Medical Information Requests (Medical Enquiries)?

A Medical Information Request—also known as a Medical Enquiry—is a spontaneous question or request for scientific information about a company’s medicinal products or related therapeutic areas. These requests can be submitted by:

  • Healthcare professionals
  • Patients
  • Consumers
  • The general public
  • Healthcare organizations
  • Other stakeholders

They may cover topics from dosage and drug–drug interactions to use in special populations, off-label questions, device operation, storage and stability, or side-effect clarifications, and can arrive via email, phone, medical representatives, or digital platforms.

These activities fall under the responsibility of a company’s scientific services or its marketing authorization holder and must comply with:

 

  • EU Directive 2001/83/EC (as amended)
  • Applicable national laws (e.g., Spain’s Law 29/2006; Royal Decree 1345/2007)
  • Promotion-related safeguards (e.g., Royal Decree 1416/1992; local circulars such as Pharmacy Circular No. 1/2000 in Madrid)
  • Industry codes and guidelines (e.g., EFPIA Code of Practice)

The guiding principles? Responses must be scientifically accurate, objective, and non-promotional, and — importantly — tailored in tone and level of detail to the recipient, always prioritizing patient safety and healthcare professional autonomy.

Why medical enquiries deserve strategic focus

While responding to medical enquiries is a regulatory requirement, it’s also a unique opportunity to showcase your company’s deep therapeutic expertise and strengthen your brand as a scientifically responsible partner. Done well, this process can:

  • Demonstrate deep knowledge and expertise in the relevant therapeutic area
  • Reinforce trust among healthcare professionals and patients by providing clear, tailored guidance
  • Support clinicians in their day-to-day practice with balanced, evidence-based information
  • Empower patients to use your products safely and effectively
  • Highlight regulatory competence through consistent, compliant processes

In short: it’s not just about compliance. It’s about credibility, expertise, and real-world impact.

Regulatory landscape: turning compliance into clarity

You know that medical enquiries fall under your scientific services and are governed by a patchwork of EU and local laws. But how can you use that framework to your advantage?

  • EU Directive 2001/83/EC mandates a dedicated scientific service for product-related information at the European level.
  • National laws (e.g., Spain’s Guarantee Law 29/2006; Royal Decree 1345/2007) and promotion-related safeguards (e.g., Royal Decree 1416/1992) layer on requirements for non-promotional, science-based communication.
  • Industry codes (for instance, the EFPIA Code of Practice) further guide tone and transparency.

Rather than seeing these rules as restrictions, the most successful companies leverage them to build consistent, credible processes—from triage and evidence review to documentation and follow-up—ensuring every response is scientifically accurate, objective, and tailored in tone and depth to the recipient.

A well-understood regulatory foundation not only satisfies auditors but also fosters internal clarity, external trust, and reinforces your role as a true scientific partner to healthcare professionals and patients alike.

The medical enquiry lifecycle: from question to confidence

Let’s look at the typical journey of a medical enquiry and what it takes to respond appropriately at each stage.

1. Submission & triage

Requests are received through various channels—contact centers, field reps, websites—and must be classified correctly. A crucial first step is distinguishing the type of requester (HCP, patient, other) and the nature of the question (on-label, off-label, urgent, etc.).

Correct triage ensures that requests are handled efficiently and routed to the right experts, minimizing delays and regulatory risk.

2. Research & information gathering

The medical information team collects data to craft an accurate response.

  • For patients, responses are based on the SmPC (Summary of Product Characteristics) and patient leaflet.
  • For HCPs, information may extend beyond the label, based on peer-reviewed literature and clinical data.

This may involve: 

  • Bibliographic searches in scientific databases (e.g. PubMed, Embase)
  • Use of keywords, MeSH terms, Boolean operators
  • Critical reading of primary sources to extract relevant, balanced data

Tailoring responses to the audience while maintaining scientific integrity is essential for compliance and impact.

3. Internal review & approval

Draft responses undergo review by cross-functional stakeholders—medical, legal, and regulatory—to ensure scientific objectivity, policy compliance, and legal soundness. Comprehensive audit trails are maintained for inspection readiness.

Robust internal oversight provides full traceability and safeguards against risks of non-compliant promotional messaging, reinforcing both regulatory integrity and brand credibility.

4. Response delivery & feedback

The final response is sent in a clear, well-referenced format appropriate for the requester. Many companies also include a feedback loop to assess satisfaction and improve the process.

A professional, audience-appropriate response enhances credibility, and every interaction is a chance to learn and improve.

Building a world-class medical information team

Delivering top-notch medical information requires more than subject-matter knowledge; it demands a blend of specialized skills and competencies:

  • Deep Therapeutic & Industry Expertise: Team members must understand the nuances of the therapeutic-area landscape, product portfolios, and the broader pharmaceutical environment — anticipating laboratory and clinical practice needs.
  • Advanced Literature-Search Mastery: Proficiency with key scientific databases (PubMed, Cochrane Library, Embase) and search tools — MeSH terms, subheadings, Boolean operators, and database algorithms — ensures fast, comprehensive evidence retrieval.
  • Critical Appraisal & Evidence Synthesis: The ability to evaluate study design, detect bias, and distill complex data underpins truly evidence-based responses.
  • Strategic Communication & Stakeholder Support: Crafting scientifically accurate, audience-appropriate messages that reinforce clinical decision-making for HCPs and guide patients in safe, effective product use.

Investing in these capabilities not only elevates response quality but also builds the robust processes you need to handle complex or novel enquiries with confidence and full compliance.

High-quality medical information isn’t just expertise — it’s grounded in rigorous policy adherence and scientific integrity. By ensuring every response is accurate, reliable, and fully aligned with regulations, you reinforce your credibility and trustworthiness in the eyes of healthcare professionals, patients, regulators, and consumers.

Turning enquiries into brand-building opportunities

Medical information requests aren’t just service interactions—they’re moments to reinforce your scientific integrity and corporate reputation:

  • Timeliness demonstrates commitment: Rapid turnaround times show stakeholders their concerns truly matter.
  • Scientific rigor prevents bias: Delivering balanced, evidence-based information—with clear acknowledgment of both benefits and limitations—ensures accuracy and objectivity.
  • Transparency builds confidence: Citing sources, methodologies, and data provenance underscores your dedication to scientific integrity.
  • Consistency reflects excellence: Applying uniform processes across all enquiries highlights operational rigor, reliability, and compliance.

By viewing each enquiry as a brand engagement, you cultivate lasting trust and differentiate your organization in a competitive market.

How QbD Group can support your medical information processes

QbD Group offers end-to-end support for handling Medical Information Requests and Enquiries, ensuring every response is compliant, scientifically sound, and strategically aligned:

  • Regulatory Alignment: Our processes are meticulously designed to satisfy EU and national legislation, including anti-promotion safeguards.
  • Scientific Excellence: Leveraging our team of seasoned medical writers and researchers, we conduct thorough literature reviews and produce high-quality, well-referenced reports.
  • Operational Efficiency: With streamlined workflows, audit-ready documentation, and real-time KPI tracking, we ensure your enquiries are handled promptly and transparently.
  • Tailored Engagement: Whether your audience is patients, HCPs, or organizational stakeholders, we adapt our communication style and depth to meet their specific needs.

Ready to transform your medical enquiry process into a strategic asset?

Contact QbD Group today to discover how we can help you strengthen your Medical Information Requests and Medical Enquiries—from regulatory compliance to scientific excellence.

Contact QbD Group today to discover how we can help you strengthen your Medical Information Requests and Medical Enquiries—from regulatory compliance to scientific excellence.

 

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

Circles-banner-short

Discover more expert content

preview_image
Blog

FDA Expands Unannounced Foreign Inspections: How to Stay Inspection Ready

Since the FDA announced in May 2025 the expansion of unannounced...
preview_image
Blog

MDR & Cybersecurity: What Your Technical File Needs to Prove

Cybersecurity has become a fundamental requirement under the Medical Device...
preview_image
Blog

Eudralex Annex 11 Revision: What Pharma Companies Need to Know Before 2026

The European Commission is revising Annex 11 of the EU GMP guidelines, and...
preview_image
Blog

Commissioning & Qualification of Temperature-Controlled Storage Equipment in Pharma

In the pharmaceutical industry, maintaining precise temperature...
preview_image
Blog

Why Effective Project Governance Matters in Global Pharmacovigilance

Pharmacovigilance (PV) is no longer just a regulatory requirement; it has...
preview_image
Blog

Update manual on borderline classification IVDR and MDR published

The revision includes clarifications for borderline cases, including red blood...
preview_image
Blog

Revised Team NB Position Paper on Best Practices for Submission of Technical Documentation under IVDR

The revision includes updates to various sections and brings the content...
preview_image
Blog

Adoption of Commission Delegated Regulation (EU) 2025/788 amending Delegated Regulation (EU) 2023/2197 as regards the date of application and new revision of MDCG 2024-14

The amendment defers the application of the rules on the assignment of Unique...
preview_image
Blog

New MDCG position paper released on the timelines of implementation of Master UDI-DI to contact lenses and spectacle frames, spectacle lenses and ready-to-wear reading spectacles

The paper explains how the Master UDI-DI solution, introduced through recent...
preview_image
Blog

Adoption of Decision 2025/1324 on expert panels in the field of medical devices

The new panel can provide scientific and clinical advice for devices intended...